Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. - Test2 - elhamkhani - TriplyDB

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

http://www.wikidata.org/entity/Q33666543

about

SYK is a critical regulator of FLT3 in acute myeloid leukemia Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Targets, models and challenges in osteoarthritis research Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer Disordered epigenetic regulation in MLL-related leukemia.NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function.Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.Genome-wide localization of small molecules.Small-molecular modulators of cancer-associated epigenetic mechanisms.AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Targeted drug discovery for pediatric leukemia.An MLL-dependent network sustains hematopoiesis.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Targeting epigenetic regulators for cancer therapy.Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer.Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.The lasting influence of LSD1 in the blood.Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.Discovery of BET bromodomain inhibitors and their role in target validation

P2860

Q24337247-DEFE9AFC-F1B8-4C34-9115-D57694651F32 Q26801573-B4D54028-B3BD-4A9A-A3F6-CBE67ECAD73F Q26850147-2821FD23-1E40-45B6-BF98-C9994A18491F Q28076086-F9D22276-796F-4DC0-8443-CA5A1150BC5C Q30422159-9F7972C0-AA91-412B-9CB1-DA172037C489 Q33601322-9FE6EBCD-5ABE-4D9A-9DF1-0218C6CFFE52 Q33835065-17AF0A61-D88B-4F9B-964C-DDF59500759F Q33847875-CB971FFE-7413-4D18-A453-E8A0664B4565 Q34306973-D1B196F6-47D5-40DB-8C18-51504A3A3DA9 Q34628002-DA7D9C90-B198-4BB7-83FE-F8DE8CA31725 Q34918857-F867D4E9-49FD-470B-B5EC-3EC7EE0473FC Q35842297-9A5AFCD2-A9F4-45E7-A122-0A95B9AED4FF Q35967446-0E684336-58E4-44EC-BB00-DD51E6F29FBE Q36199628-280E7EB4-82CD-4CE1-9314-2D189525F808 Q36250669-C1DCE543-4C85-4C77-BB56-C22AE1334D7F Q36730426-E18E8666-080C-417A-925A-E9DA1E3BD254 Q36906949-1A8D1D73-38FC-462C-977B-E40E31DFC09B Q36956610-4BF98BF2-D208-43A2-8901-AA11DDED785C Q36989223-A0ADB89F-72E9-4DF9-939A-33187176DA0F Q37031831-A697FD97-8291-448B-95A0-D7AC3363A7B2 Q38161393-EA1D570C-CEF6-4ECB-A061-0B7C1D8A9440 Q38191266-1C4AB861-537E-4991-ADF3-5C574E2A64B4 Q38641649-33638E43-C521-4170-8FFB-1EEFE6416241 Q38714672-ACC1578D-A438-4DF5-AF74-3BD3314E0188 Q38830100-1A0B2C3A-1952-41C9-99ED-2AF917C2D276 Q41317361-23C7FC11-B66F-4B98-9A0F-B269EE9694D2 Q41616680-6C6EAA92-AD58-4B0F-B320-135741125038 Q41947883-1671E49F-30F9-4C1E-863F-4050D33CAD90 Q46932033-ED2F8C95-C00E-4463-95ED-35EFABDB0D45 Q54933470-9933AA59-600A-44DE-B41D-A4861FD49B69

P2860

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

http://www.wikidata.org/entity/Q33666543

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@ast

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@en

type

label

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@ast

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@en

prefLabel

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@ast

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@en

P1433

Q33666543-B3BF7F28-D052-4B4B-8D26-F936B04CFD87

P1476

Q33666543-B4F8D466-7ADD-4B12-8778-2BDE4394AF96

P2093

Q33666543-703E920E-BFAF-438C-BF03-3BF643994D81

Q33666543-99001FCF-7756-486B-B9AF-A43E1D8511CE

Q33666543-E8369ACA-014D-4CBE-9F26-1F387C89D63F

P2860

Q33666543-030EFDD3-DA96-4B6D-B093-BF2F8754D364

Q33666543-07C67E96-D5B6-4B6E-95DD-0A7F1E4642BA

Q33666543-0AD1E214-544F-4E34-91CC-94F9895B1A28

Q33666543-12C63826-80D0-4E53-B639-676939F41EB4

Q33666543-13033DD7-F3A3-4570-87C4-3D5B0FA0123F

Q33666543-13367003-57A3-42DC-810D-2B54F6F8BAE5

Q33666543-1767D903-C9A4-44EC-AA8A-AA9EB5FC68F1

Q33666543-17CC8821-F51A-449A-8E57-BB6CC384BCFC

Q33666543-18619935-DD0B-4E9C-8CDD-D2AC102D13C8

Q33666543-1F42E5FD-CF19-4EDC-9193-35B40E373D17

P304

Q33666543-B03FD88B-6856-4CDE-9BD5-C55DFD2C821E

P31

Q33666543-D24D21DA-C88F-4F17-B4DE-824FF57CBEBB

P356

Q33666543-99A5509A-EFFA-4956-9D82-02F5B4BDFE10

P433

Q33666543-7D917D90-58EB-4155-BBEB-C4AF629E65FF

P478

Q33666543-2FD506F7-123B-49BD-97EB-9FA5977A0CE3

P577

Q33666543-23A13C8E-4C00-45D9-86B3-CA4777D77FA7

P698

Q33666543-75A23E62-AB71-4D63-B457-B72ACF17B1D1

P921

Q33666543-50661AA7-4AAE-42BD-B86C-0A8EE59140D4

P932

Q33666543-B10586D1-7806-481D-A797-052766CB7543

P356

J.IT.2012.06.002

P1433

Trends in Immunology

P1476

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

@en

P2093

Aniruddha J Deshpande

http://www.w3.org/2001/XMLSchema#string

James Bradner

http://www.w3.org/2001/XMLSchema#string

Scott A Armstrong

http://www.w3.org/2001/XMLSchema#string

P2860

CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription

Selective inhibition of BET bromodomains

Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)

Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis

ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias

MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein

P304

563-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IT.2012.06.002

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22867873

http://www.w3.org/2001/XMLSchema#string

P921

P932

4034385

http://www.w3.org/2001/XMLSchema#string